Revolution Medicines Q1 Net Loss Widens

Market Closed – Nasdaq			5-day change	1st Jan Change
37.66 ^USD	+0.59%		-6.74%	-13.90%

Published on 05/07/2025 at 17:04

This article is reserved for members

Unlock the article: REGISTER NOW!

Revolution Medicines Q1 Net Loss Widens	05:04pm	MT
Earnings Flash (RVMD) Revolution Medicines Q1 Loss $1.13 Vs. FactSet Est. Loss $1.10	04:49pm	MT
Sector Update: Health Care Stocks Swing Between Small Gains, Losses	Apr. 28	MT
Revolution Medicines Shares Rise on ‘Encouraging’ Phase 1 Lung Cancer Trial Data	Apr. 28	MT
Revolution Medicines, Inc. Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting	Apr. 27	CI
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says	Apr. 03	MT
Revolution Medicines, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 08:00 AM	Mar. 11
Revolution Medicines Q4 Net Loss Narrows	Feb. 26	MT
Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99	Feb. 26	MT
Revolution Medicines, Inc., Q4 2024 Earnings Call, Feb 26, 2025	Feb. 26
Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 26	CI
Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2025	Feb. 26	CI
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025.	Jan. 17	CI
Certain Stock Options of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025.	Jan. 17	CI
Certain Common Stock of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025.	Jan. 17	CI
Revolution Medicines, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 10:30 AM	Jan. 13
UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating	Jan. 08	MT
Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating	Dec. 06	MT
Revolution Medicines Closes Offering of 16.6 Million Shares	Dec. 05	MT
Revolution Medicines Prices $45 Million Stock, Warrant Offering	Dec. 04	MT
Revolution Medicines Launches $600 Million Offering of Common Shares	Dec. 02	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating	Dec. 02	MT
Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies	Dec. 02	MT

Duration

Period

RVMD: Dynamic Chart

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

More about the company

Sell

Buy

Average target price

72.33USD

Spread / Average Target

+93.20%

Consensus

Sweden eases alcohol monopoly one bottle at a time

Pembina Pipeline Corporation Announces Redemption Of Series 19 Preferred Shares

AFLAC Inc Files For Offering Of ¥35 Billion 1.726% Senior Notes Due 2030, ¥23.4 Billion 2.003% Senior Notes Due 2032 -SEC Filing

Russia sets grain export taxes for June 4 to June 10

Equities Fall Intraday After Trump Accuses China of Violating Trade Pact

TSMC to Consider Building Advanced Chip Plant in UAE, Bloomberg Reports

Brazil 2025 Robusta harvest in full swing and could beat estimates, experts say

Palantir Selected by Trump to Compile Data on Americans

Oppenheimer Adjusts Price Target on Cooper to $95 From $107

Ethereum’s Pectra update meets expectations, edges closer to Fusaka

NYPD officers ensnared in Bitcoin investor torture case

Sweden eases alcohol monopoly one bottle at a time

ETH posts first monthly positive returns in 2025 following whale and ETF buying pressure

How to buy Bitcoin in the USA

Pembina Pipeline Corporation Announces Redemption Of Series 19 Preferred Shares

Sweden eases alcohol monopoly one bottle at a time

Pembina Pipeline Corporation Announces Redemption Of Series 19 Preferred Shares

AFLAC Inc Files For Offering Of ¥35 Billion 1.726% Senior Notes Due 2030, ¥23.4 Billion 2.003% Senior Notes Due 2032 -SEC Filing

Russia sets grain export taxes for June 4 to June 10

Equities Fall Intraday After Trump Accuses China of Violating Trade Pact

TSMC to Consider Building Advanced Chip Plant in UAE, Bloomberg Reports

Brazil 2025 Robusta harvest in full swing and could beat estimates, experts say

Palantir Selected by Trump to Compile Data on Americans

Oppenheimer Adjusts Price Target on Cooper to $95 From $107

Ethereum’s Pectra update meets expectations, edges closer to Fusaka

NYPD officers ensnared in Bitcoin investor torture case

Sweden eases alcohol monopoly one bottle at a time

ETH posts first monthly positive returns in 2025 following whale and ETF buying pressure

How to buy Bitcoin in the USA

Pembina Pipeline Corporation Announces Redemption Of Series 19 Preferred Shares

Revolution Medicines Q1 Net Loss Widens

Related Posts

Ethereum’s Pectra update meets expectations, edges closer to Fusaka

NYPD officers ensnared in Bitcoin investor torture case

6 Minutes Of Retail Trader Research Drives 20% Of Stock Market Volume

Forexlive Americas FX news wrap 7 May: Fed and Chair Powell stays noncommitted

Stock Market Today: Stocks Rise Despite Stagflation Risk

Scotland’s Lomond School And Saifedean Ammous Launch New Bitcoin Scholarship Program

Recent Posts

Navigate Site

Revolution Medicines Q1 Net Loss Widens

Related Posts

Recent Posts

Navigate Site

Follow Us